Our data demonstrated that nanoandaliman at low dose (25 mg/kg bw) showed a significant effect on suppressing the expression of cox-2, il-1b, inos, and mmp1 genes, indicating its potency as an anti-arthritic and anti-inflammatory agent for the management of arthritis. Here, MMP1 is linked to arthritic joint disease.